Experimental chemotherapy against Trypanosoma cruzi infection: Essential role of endogenous interferon-γ in mediating parasitologic cure

Journal of Infectious Diseases

Volumn 186, Issue 6, 2002, Pages 823-828

  Romanha, Alvaro J ^a   Alves, Rosana O ^a   Murta, Silvane M F ^a   Silva, João S ^c   Ropert, Catherine ^a   Gazzinelli, Ricardo T ^a,b  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BENZNIDAZOLE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; NITRIC OXIDE SYNTHASE; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMOTHERAPY; DRUG EFFICACY; FEMALE; IMMUNE SYSTEM; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TREATMENT OUTCOME; TRYPANOSOMA CRUZI; TRYPANOSOMIASIS;

ANIMALS; ANTIGENS, CD; CHAGAS DISEASE; FEMALE; GENE DELETION; INTERFERON TYPE II; INTERLEUKIN-12; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITROIMIDAZOLES; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; TIME FACTORS; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 0037105691     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/342415     Document Type: Article

References (31)

1. Chagas' disease
2. Chemotherapy of Chagas' disease: The how and the why
3. Human antiprotozoal therapy: Past, present, and future
4. Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox
5. In-vivo treatment with benznidazole enhances phagocytosis, parasite destruction and cytokine release by macrophages during infection with a drug-susceptible but not with a derived drug-resistant Trypanosoma cruzi population
6. Interleukin-12 enhances in vivo parasiticidal effect of benznidazole during acute experimental infection with a naturally drug-resistant strain of Trypanosoma cruzi
7. Immunological and clinical evaluation of chagasic patients subjected to chemotherapy during the acute phase of Trypanosoma cruzi infection 14-30 years ago
8. Sobre uma cepa de Trypanosoma cruzi altamente virulenta para o camundongo branco
9. Therapeutic activity and criterion of cure in mice experimentally infected with Trypanosoma cruzi
10. Growth and differentiation in Trypanosoma cruzi. I. Origin of metacyclic trypanosome in liquid media
11. Interferon-γ and tumor necrosis factor induce the L-arginine-dependent cytotoxic effector mechanism in murine macrophages
12. The microbicidal activity of interferon-γ-treated macrophages against Trypanosoma cruzi involves an L-arginine-dependent, nitrogen oxide-mediated mechanism inhibitable by interleukin-10 and transforming growth factor-β
13. Nitric oxide is involved in the control of Trypanosoma cruzi-induced parasitemia and directly kills parasite in vitro
14. Tumor necrosis factor alpha mediates resistance to Trypanosoma cruzi in mice by inducing nitric oxide production in infected gamma interferon-activated macrophages
15. Interactions between immunity and chemotherapy in the treatment of the trypanosomiases and leishmaniases
16. IL-12 mediates resistance to Trypanosoma cruzi in mice and is produced by murine macrophages in response to live trypomastigotes
17. Results of treatment in mice immunosuppressed inoculated with different Trypanosoma cruzi strains
18. In vivo administration of recombinant IFN-gamma induces macrophage activation, and prevents acute disease, immune suppression, and death in experimental Trypanosoma cruzi infections
19. Endogenous IFN-gamma is required for resistance to acute Trypanosoma cruzi infection in mice
20. Interleukin 10 and interferon gamma regulation of experimental Trypanosoma cruzi infection
21. Protected Trypanosoma cruzi infection in rats born to mothers receiving interferon-gamma during gestation is associated with a decreased intra-macrophage parasite growth and preferential synthesis of specific IgG2b antibodies
22. Chagas' disease: American trypanosomiasis
23. The role of interferon-γ in the treatment of visceral and diffuse cutaneous leishmaniasis
24. Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon gamma
25. Interferon-gamma and host antimicrobial defense: Current and future clinical applications
26. Chagasic meningoencephalitis with detection of Trypanosoma cruzi in the cerebrospinal fluid of an immunodepressed patient
27. Pathology of patients with Chagas' disease and acquired immunodeficiency syndrome
28. Trypanosoma cruzi meningoencephalitis in HIV-infected patients
29. Cysteine protease inhibitors as chemotherapy for parasitic infections
30. In vivo activity of the bis-triazole D0870 against drug-susceptible and drug-resistant strains of the protozoan Trypanosoma cruzi
31. Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts